Novintum BioScience, a cancer metabolism company, is developing first-in-class treatments that aim to prolong the lives of cancer patients by preventing treatment resistance and delaying relapse. Novintum Bio has an innovative approach to tackling cancer resistance, by targeting the mitochondria in Treatment Resistant Cells (TRCs are also described in the scientific literature as Polyploid Giant Cancer Cells – PGCCs).
Novintum Bio has a unique approach to tackling cancer resistance that is focused on mitochondria, the organelle that regulates metabolism, including energy production, cell signalling, apoptosis and growth.Learn more
Treatment Resistant Cells (TRCs) are formed in response to stress, either by the tumour metabolic environment (low nutrient, low O2, low pH) or induced by treatment, and are commonly found in biopsies from tumours.Learn more
Novintum Bio’s proprietary ‘Novi’ technology platforms are able to design (NoviChem) and test (NoviAssay) new compounds for targeting and destroying Treatment Resistant Cells across a range of cancer types.
Novintum BioScience, a cancer metabolism company, is developing first-in-class treatments that aim to prolong the lives of cancer patients by preventing resistance and delaying relapse of this devastating disease.
Novintum Bio’s pipeline consists of novel Mitochondrial Metabolism Disruptors (MMDs) that contain a drug known to inhibit protein synthesis, coupled with a Mitochondria Targeting Group (MTG), that delivers the drug to mitochondria.